Opinion|Videos|March 31, 2026
Navigating TKI Selection in HER2-Mutant NSCLC
Author(s)Martin Dietrich, MD, PhD, Ticiana A. Leal, MD
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss factors that inform sevabertinib and zongertinib treatment selection in HER2-mutant NSCLC.
Advertisement
Episodes in this series
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, explore factors influencing selection between HER2-directed tyrosine kinase inhibitors such as sevabertinib and zongertinib. Dietrich compares efficacy and safety profiles across available agents, noting how toxicity considerations may drive individualized treatment choices. Leal emphasizes the importance of tailoring therapy based on patient comorbidities and tolerability to optimize outcomes.
Advertisement
Related to this article
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Alcohol-attributable cancer deaths in the U.S. doubled from about 11,400 in 1990 to more than 23,100 in 2023.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis
5